PriceTargets.com logo

Kaleido Biosciences - KLDO Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 11/20/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for KLDO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kaleido Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KLDO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KLDO

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Kaleido Biosciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for KLDO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Kaleido Biosciences. This rating has held steady since March 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/4/2022Chardan CapitalDowngradeBuy ➝ Neutral$3.00 ➝ $1.70
1/31/2022Chardan CapitalLower TargetBuy$11.00 ➝ $3.00
11/12/2021Chardan CapitalLower TargetBuy$15.00 ➝ $11.00
11/3/2021JMP SecuritiesLower TargetMarket Outperform$25.00 ➝ $22.00
10/19/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight$3.00
10/8/2021JMP SecuritiesReiterated RatingBuy$25.00
7/9/2021Chardan CapitalInitiated CoverageBuy$15.00
7/1/2021Chardan CapitalReiterated RatingBuy
3/8/2021Morgan StanleyLower TargetEqual Weight$13.00 ➝ $12.00
2/9/2021Piper SandlerInitiated CoverageOverweight$19.00
1/19/2021Morgan StanleyBoost TargetEqual Weight$8.00 ➝ $13.00
1/14/2021Chardan CapitalBoost TargetPositive ➝ Buy$10.00 ➝ $17.50
12/23/2020JMP SecuritiesInitiated CoverageOutperform$22.00
10/14/2020JPMorgan Chase & Co.Initiated CoverageUnderweight
8/10/2020Morgan StanleyBoost TargetEqual Weight$7.00 ➝ $8.00
7/15/2020Morgan StanleyLower TargetEqual Weight$8.00 ➝ $7.00
5/21/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$8.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Kaleido Biosciences logo
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

330 shs

Average Volume

3,238 shs

Market Capitalization

$6.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Kaleido Biosciences?

The following Wall Street research analysts have issued reports on Kaleido Biosciences in the last twelve months:
View the latest analyst ratings for KLDO.

What is the current price target for Kaleido Biosciences?

0 Wall Street analysts have set twelve-month price targets for Kaleido Biosciences in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Kaleido Biosciences in the next year.
View the latest price targets for KLDO.

What is the current consensus analyst rating for Kaleido Biosciences?

Kaleido Biosciences currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for KLDO.

What other companies compete with Kaleido Biosciences?

Other companies that are similar to Kaleido Biosciences include Abits Group, CXApp, Hitek Global, GigaMedia and GSE Systems. Learn More about companies similar to Kaleido Biosciences.

How do I contact Kaleido Biosciences' investor relations team?

The company's listed phone number is (617) 674-9000. The official website for Kaleido Biosciences is www.kaleido.com. Learn More about contacing Kaleido Biosciences investor relations.